With reference to the main known acquired resistance mechanisms to the antiangiogenic monoclonal antibody plus EGFR-TKI combinations in EGFR+ advanced NSCLC patients (T790M substitution and MET amplification), we can report that, while osimertinib treatment in T790M+ patients still represents the only approved treatment, MET-TKIs will likely change this status quo in the near future. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.